Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HMBD-001 |
Synonyms | |
Therapy Description |
HMBD-001 is a monoclonal antibody that binds ERBB3 (HER3) and prevents heterodimer formation, potentially inhibiting tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P197). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HMBD-001 | HMBD001|HMBD 001 | HER3 (ERBB3) Antibody 23 | HMBD-001 is a monoclonal antibody that binds ERBB3 (HER3) and prevents heterodimer formation, potentially inhibiting tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P197). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05919537 | Phase Ib/II | Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | Recruiting | AUS | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |